Zobrazeno 1 - 10
of 491
pro vyhledávání: '"A N Nafziger"'
Autor:
Michael R. Fetell, Anne N. Nafziger, Joseph S. Bertino, Robert R. Goodman, Guy M. McKhann, Michael B. Sisti, Manisha Desai, May Huang, Jeffrey N. Bruce, Casilda Balmaceda, Johnson Chen, Robert L. Fine
Supplementary Tables 1-6, Figures 1-4 from Randomized Study of Paclitaxel and Tamoxifen Deposition into Human Brain Tumors: Implications for the Treatment of Metastatic Brain Tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63459cc1adaf3532cb46eaaa27f8dc14
https://doi.org/10.1158/1078-0432.22441911.v1
https://doi.org/10.1158/1078-0432.22441911.v1
Autor:
Michael R. Fetell, Anne N. Nafziger, Joseph S. Bertino, Robert R. Goodman, Guy M. McKhann, Michael B. Sisti, Manisha Desai, May Huang, Jeffrey N. Bruce, Casilda Balmaceda, Johnson Chen, Robert L. Fine
Purpose: Drug resistance in brain tumors is partially mediated by the blood-brain barrier of which a key component is P-glycoprotein, which is highly expressed in cerebral capillaries. Tamoxifen is a nontoxic inhibitor of P-glycoprotein. This trial a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d27b8c38a3cc37df09a348dcee49b56f
https://doi.org/10.1158/1078-0432.c.6518784.v1
https://doi.org/10.1158/1078-0432.c.6518784.v1
Autor:
Sandrine Turpault, Joseph D. Ma, Edmund V. Capparelli, Lana Tran, Joseph S. Bertino, Angela D. M. Kashuba, Anne N. Nafziger, Mina Nikanjam
Publikováno v:
European Journal of Clinical Pharmacology. 77:1349-1356
S-warfarin is used to phenotype cytochrome P450 (CYP) 2C9 activity. This study evaluated S-warfarin limited sampling strategy with a population pharmacokinetic (PK) approach to estimate CYP2C9 activity in healthy adults. In 6 previously published stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0149283387db40737dd9597a6ce1a06e
https://doi.org/10.1007/s00228-021-03123-y
https://doi.org/10.1007/s00228-021-03123-y
Autor:
Anne N. Nafziger, C Michael White
Publikováno v:
The Journal of Clinical Pharmacology. 61
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::02565dfc2e7b3b2226f53de39b9193e8
https://doi.org/10.1002/jcph.1921
https://doi.org/10.1002/jcph.1921
Autor:
Jincheng Yang, S. Aubrey Stoch, Anne N. Nafziger, Howard E. Greenberg, Shirley M. Tsunoda, Joseph S. Bertino, Joseph D. Ma, Edmund V. Capparelli, Mina Nikanjam, Scott R. Penzak
Publikováno v:
The Journal of Clinical Pharmacology. 59:1495-1504
We have previously described a midazolam limited sampling strategy employing a population pharmacokinetic (PK) approach to estimate constitutive cytochrome P450 (CYP) 3A activity. This study evaluated expansion of this approach to estimate CYP3A cons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dddba3bbc46271c3004dd91f442eb89f
https://doi.org/10.1002/jcph.1440
https://doi.org/10.1002/jcph.1440
Publikováno v:
Journal of clinical pharmacologyReferences. 61
Use of US Food and Drug Administration-approved substances of abuse has innate risks due to pharmacologic and pharmacokinetic properties of the medications, but the risk when using nonapproved drug products is much greater. Unbeknownst to the user, t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b67fa2353e24c2079e348597a481c0cb
https://pubmed.ncbi.nlm.nih.gov/34396559
https://pubmed.ncbi.nlm.nih.gov/34396559
Autor:
Lana, Tran, Mina, Nikanjam, Edmund V, Capparelli, Joseph S, Bertino, Anne N, Nafziger, Angela D M, Kashuba, Sandrine, Turpault, Joseph D, Ma
Publikováno v:
European journal of clinical pharmacology. 77(9)
S-warfarin is used to phenotype cytochrome P450 (CYP) 2C9 activity. This study evaluated S-warfarin limited sampling strategy with a population pharmacokinetic (PK) approach to estimate CYP2C9 activity in healthy adults.In 6 previously published stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::943aa690e63906a96d1f661c4560595d
https://pubmed.ncbi.nlm.nih.gov/33754183
https://pubmed.ncbi.nlm.nih.gov/33754183
Autor:
Robert L. Barkin, Anne N. Nafziger
Publikováno v:
The Journal of Clinical Pharmacology. 58:1111-1122
This is an article in the Core Entrustables in Clinical Pharmacology series that describes opioid therapy in acute and chronic pain. Opioid use during surgical procedures or anesthesia is not discussed. Basic pharmacokinetic and pharmacodynamic prope
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23f69ecfb01b6526adcb461d61ecd917
https://doi.org/10.1002/jcph.1276
https://doi.org/10.1002/jcph.1276
Autor:
James R. Sanders, Dean N. Nafziger
Publikováno v:
Journal of MultiDisciplinary Evaluation, Vol 7, Iss 15 (2011)
Originally published as Paper #7, Occasional Paper Series, April, 1976 * This paper was prepared under contract support from the Alaska Department of Education to the Northwest Regional Educational Laboratory.
Externí odkaz:
https://doaj.org/article/e20b076adca8441fa4b90d09dd6b9e29
Autor:
Michael J. Fossler, Kelly A. Arscott, David A. Burt, Franck Skobieranda, Kristina Cochrane, Anne N. Nafziger
Publikováno v:
Clinical Pharmacology in Drug Development
Oliceridine is a G protein–biased ligand at the μ‐opioid receptor in development for treatment of moderate to severe acute pain. A phase 1, open‐label, single‐dose study investigated the pharmacokinetics and safety of oliceridine 0.5 mg intr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::899d4327a8282815e199d45a7f0100c9
https://pubmed.ncbi.nlm.nih.gov/31697049
https://pubmed.ncbi.nlm.nih.gov/31697049